• 1
    St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994; 89: 6875.
  • 2
    Savoye C, Equine O, Tricot O, et al. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol. 2006; 98: 11449.
  • 3
    Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990; 81: 116172.
  • 4
    Gaudron P, Eilles C, Kugler I, et al. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation. 1993; 87: 75563.
  • 5
    Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101: 29818.
  • 6
    Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003; 107: 278692.
  • 7
    Nagaya N, Nishikimi T, Goto Y, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J. 1998; 135: 218.
  • 8
    Nilsson JC, Groenning BA, Nielsen G, et al. Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J. 2002; 143: 696702.
  • 9
    Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J. 2008; 9: 211624.
  • 10
    Fertin M, Hennache B, Hamon M, et al. Multimarker approach for the prediction of left ventricular remodeling after acute myocardial infarction. Serial assessment of B-type natriuretic peptide, troponine I, and C-reactive protein. Am J Cardiol. 2010; 106: 14106.
  • 11
    Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997; 96: 197682.
  • 12
    Pfeffer MA, Pfeffer JM, Steinberg C, et al. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985; 72: 40612.
  • 13
    Dubois E, Richard V, Mulder P, et al. Decreased Serine207-phosphorylated of troponin T as a biomarker for left ventricular remodeling after myocardial infarction. Eur Heart J. 2011; 32: 11523.
  • 14
    Sundström J, Evans JC, Benjamin EJ, et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J. 2004; 25: 150916.
  • 15
    Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004; 109: 16749.
  • 16
    Mulder P, Mellin V, Favre J, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008; 29: 21719.
  • 17
    Banquet S, Gomez E, Nicol L, et al. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation. 2011; 124: 105969.
  • 18
    Steinberg TH, Agnew BJ, Gee KR, et al. Global quantitative phosphoprotein analysis using Multiplexed Proteomics technology. Proteomics. 2003; 3: 112844.
  • 19
    Kramer F, Sandner P, Klein M, et al. Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat. Biomarkers. 2008; 13: 27081.
  • 20
    Santos-Araujo C, Roncon-Albuquerque R, Moreira-Rodrigues M, et al. Local modulation of the natriuretic peptide system in the rat remnant kidney. Nephrol Dial Transplant. 2009; 24: 177482.
  • 21
    Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358: 214859.
  • 22
    de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003; 362: 31622.
  • 23
    Ohlmann P, Jaquemin L, Morel O, et al. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. Am Heart J. 2006; 152: 11617.
  • 24
    Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol. 2006; 47: 9628.
  • 25
    Cavallero S, Gonzalez GE, Seropian IM, et al. Ventricular function and natriuretic peptides in sequentiallly combined models of hypertension. Am J Physiol Heart Circ Physiol. 2010; 298: H12909.
  • 26
    Kohno M, Horio T, Yoshiyama M, et al. Accelerated secretion of brain natriuretic peptide from the hypertrophied ventricles in experimental malignant hypertension. Hypertension. 1992; 19: 20611.
  • 27
    Swedberg K, Komajda M, Böhm M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010; 376: 88694.
  • 28
    Ceconi C, Comini L, Suffredini S, et al. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol. 2011; 300: H36673.